| Literature DB >> 33919412 |
Ling-Sai Chang1,2, Ken-Pen Weng3,4,5, Jia-Huei Yan1,2, Wan-Shan Lo1, Mindy Ming-Huey Guo1,2, Ying-Hsien Huang1,2, Ho-Chang Kuo1,2.
Abstract
(1) Background: Desquamation is a common characteristic of Kawasaki disease (KD). In this study, we analyzed patients' varying desquamation levels in their hands or feet, in correlation with clinical presentation, to assess the relationship. (2)Entities:
Keywords: Kawasaki disease; coronary artery lesion; desquamation
Year: 2021 PMID: 33919412 PMCID: PMC8143344 DOI: 10.3390/children8050317
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1The illustration to identify the grade of desquamation.
Figure 2The desquamation of hands; the black arrows point out the margin of peeling; (A): grade 1; (B): grade 2; (C): grade 3.
Figure 3The desquamation of feet; the black arrows point out the margin of peeling; (A): grade 1; (B): grade 2; (C): grade 3.
Patients’ laboratory data—desquamation positive or negative.
| Desquamation Negative | Desquamation Positive | ||
|---|---|---|---|
|
| 20 (17.9%) | 92 (82.1%) | |
|
| 14/20 (70.0%) | 52/92 (56.5%) | 0.322 |
|
| 1.1 (0.6–1.6) | 1.4 (0.8–2.6) | 0.063 |
|
| 12.7 (9.7–16.4) | 12.5 (10.1–14.4) | 0.536 |
|
| 11.0 (10.3–11.9) | 11.1 (10.3–12.0) | 0.811 |
|
| 333.0 (253.5–434.8) | 361.0 (285.5–435.8) | 0.416 |
|
| 53.7 (45.0–65.6) | 61.0 (47.1–72.0) | 0.173 |
|
| 0 (0–0) | 0 (0–0) | 1.000 |
|
| 29.2 (25.4–45.1) | 29.2 (20.0–40.0) | 0.368 |
|
| 7.1 (3.2–10.1) | 5.0 (3.8–8.0) | 0.277 |
|
| 35.8 (14.7–64.0) | 58.4 (28.6–116.1) | 0.078 |
|
| 42.0 (32.5–62.8) | 35.0 (25.0–75.0) | 0.342 |
|
| 23.5 (16.0–93.3) | 45.0 (18.0–92.8) | 0.268 |
|
| 4.0 (3.5–4.3) | 3.9 (3.6–4.2) | 0.852 |
|
| 3.0 (0–34.0) | 6.0 (0–24.0) | 0.950 |
|
| 1/20 (5.0%) | 6/92 (6.5%) | 1.000 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; IVIG, intravenous immunoglobulin; WBC, white blood cells.
Patients’ laboratory data of Kawasaki disease before IVIG (with hands’ desquamation positive or not).
| Hands’ Desquamation | Hands’ DesquaMation | Low-Grade Desquamation | High-Grade Desquamation | |||
|---|---|---|---|---|---|---|
|
| 21 | 91 | 77 | 14 | ||
|
| 14/21 (66.7%) | 52/91 (57.1%) | 0.470 | 44/77 (57.1%) | 8/14 (57.1%) | 1.000 |
|
| 1.0 (0.6–1.6) | 1.5 (0.7–2.6) |
| 1.4 (0.7–2.5) | 2.2 (1.3–4.2) |
|
|
| 12.4 (9.8–16.2) | 12.5 (10.1–14.4) | 0.568 | 12.5 (9.8–14.4) | 12.4 (11.4–14.8) | 0.460 |
|
| 10.7 (10.3–11.9) | 11.1 (10.3–12) | 0.723 | 11.1 (10.2–12) | 11.2 (10.3–11.8) | 0.697 |
|
| 341.0 (254.0–433.5) | 360.0 (284.0–437.0) | 0.519 | 352.0 (287.0–431.0) | 365.5 (262.3–447.0) | 0.980 |
|
| 51.3 (45.3–65.3) | 61.0 (48.1–72.0) | 0.123 | 59.0 (46.2–70.7) | 69.8 (60.7–76.8) |
|
|
| 0 (0–0) | 0 (0–0) | 0.900 | 0 (0–0) | 0 (0–1) | 0.702 |
|
| 29.7 (25.6–45.7) | 29.1 (20.0–40.0) | 0.236 | 30.0 (21.6–40.1) | 20.1 (14.6–31.1) |
|
|
| 7.0 (3.1–9.7) | 5.0 (3.9–8.0) | 0.412 | 5.5 (4.0–8.9) | 4.1 (2.8–4.9) |
|
|
| 37.4 (15.3–65.0) | 58.2 (28.1–115.1) | 0.145 | 57.7 (29.0–104.5) | 101.3 (22.2–177.3) | 0.324 |
|
| 42.0 (34.0–86.0) | 35.0 (25.0–69.8) | 0.214 | 35.0 (26.0–64.5) | 34.0 (25.0–178.5) | 0.923 |
|
| 24.0 (16.0–95.0) | 43.0 (18.0–88.0) | 0.395 | 39.0 (18.3–82.5) | 55.0 (15.0–237.0) | 0.935 |
|
| 4.0 (3.5–4.3) | 3.9 (3.6–4.2) | 0.852 | 3.9 (3.5–4.2) | 4.1 (3.9–4.4) | 0.070 |
|
| 3.0 (0–28.5) | 6.0 (0–24.0) | 0.817 | 6.0 (0–21.0) | 6.0 (0–145.5) | 0.395 |
|
| 1/21 (4.8%) | 6/91 (6.6%) | 1.000 | 5/77(6.5%) | 1/14 (7.1%) | 1.000 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; IVIG, intravenous immunoglobulin; WBC, white blood cells. * p < 0.05.
Patients’ laboratory data of Kawasaki disease before IVIG (with feet’s desquamation positive or not).
| Feet’s Desquamation | Feet’s Desquamation | Low-Grade Desquamation | High-Grade Desquamation | |||
|---|---|---|---|---|---|---|
|
| 39 | 63 | 54 | 9 | ||
|
| 27/39 (69.2%) | 32/63 (50.8%) | 0.067 | 27/54 (50.0%) | 5/9 (55.6%) | 1.000 |
|
| 1.1 (0.7–1.9) | 1.6 (0.7–2.5) | 0.185 | 1.6 (0.7–2.2) | 1.4 (1.1–3.6) | 0.327 |
|
| 11.3 (9.2–15.2) | 12.5 (10.5–14.4) | 0.610 | 12.3 (10.2–14.0) | 14.0 (12.8–17.0) |
|
|
| 11.3 (10.3–12.0) | 10.9 (10.2–11.7) | 0.484 | 10.9 (10.2–11.9) | 10.7 (10.2–11.7) | 0.746 |
|
| 325.0 (255.0–431.0) | 375.0 (299.0–441.0) | 0.094 | 376.5 (297.3–442.3) | 371.0 (313.0–449.5) | 0.912 |
|
| 56.2 (44.6–68.0) | 62.0 (51.0–72.0) | 0.300 | 61.0 (49.8–69.8) | 63.0 (58.4–74.3) | 0.249 |
|
| 0 (0–0) | 0 (0–0) | 0.961 | 0 (0–0) | 0 (0–0) | 0.528 |
|
| 29.7 (20.0–44.3) | 29.0 (21.2–39.0) | 0.498 | 28.5 (21.8–39.3) | 29 (16.9–33.3) | 0.539 |
|
| 7.0 (3.8–10.0) | 4.7 (3.1–7.0) | 0.070 | 5.0 (3.4–7.9) | 4.0 (3.0–4.8) | 0.098 |
|
| 39.3 (14.1–67.6) | 58.3 (32.1–122.1) |
| 58.3 (32.1–119.8) | 76.3 (29.3–179.7) | 0.845 |
|
| 42.5 (32.3–93.5) | 34.0 (25.0–68.5) |
| 34.0 (25.5–99.5) | 25.0 (21.0–47.0) | 0.155 |
|
| 34.5 (18.0–107.3) | 38.5 (17.0–74.3) | 0.635 | 47.5 (17.8–77.3) | 23.5 (14.0–71.0) | 0.495 |
|
| 3.9 (3.5–4.3) | 4.0 (3.6–4.2) | 0.905 | 4.0 (3.6–4.2) | 4.0 (3.6–4.4) | 0.469 |
|
| 3.0 (0–34.0) | 6.0 (0–24.3) | 0.763 | 6.0 (0–21.8) | 4.5 (0–142.8) | 0.931 |
|
| 2/39 (5.1%) | 4/63 (6.3%) | 1.000 | 4/54 | 0/9 | 1.000 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; IVIG, intravenous immunoglobulin; WBC, white blood cells. * p < 0.05.
CAA formation incidence in subgroups.
| CAA a (−) | CAA (+) | ||
|---|---|---|---|
| Total desquamation (+) | 59/71 (83.1%) | 33/41 (80.5%) | 0.800 |
| Hands | |||
| Desquamation (+) | 58/71 (81.7%) | 33/41 (80.5%) | 1.000 |
| High-grade | 13/58 (22.4%) | 1/33 (3.0%) |
|
| Feet | |||
| Desquamation (+) | 42/67 (62.7%) | 21/35 (60.0%) | 0.832 |
| High-grade | 8/42 (19.0%) | 1/21 (4.5%) | 0.159 |
a CAA, Coronary artery abnormalities. * p < 0.05.